SALINOMYCIN
Salinomycin is an ionophore antibiotic that transports potassium across cell membranes, disrupting energy metabolism in bacteria and parasites. It is also studied for anticancer properties. Side effects include muscle weakness, neurotoxicity, GI upset, and, at high doses, cardiotoxicity. Only GMP materials will be supplied, logistics all according to GDP.
About MedicaPharma
MedicaPharma distributes high-quality active pharmaceutical ingredients (APIs) to hospitals, commercial (compounding) pharmacies, research institutes, and universities worldwide.
Network of over +400 GMP API producers
Let us handle your sourcing / supply activities. Highly experienced in sourcing specialty raw pharmaceutical ingredients from niche GMP manufacturers around the world.
Why Choose MedicaPharma
Niche API specialist - Pro-active supply partner - High service level - Global network - Logistics according to GDP regulations
Product Description
Mechanism of Action
SALINOMYCIN displays a multidimensional biochemical activity profile integrating modulation of enzymatic pathways, receptormediated signalling, mitochondrial bioenergetics, oxidativestress homeostasis, ionchannel dynamics, membrane structural behaviour and transcriptionfactor regulation. Structural modelling suggests interactions with catalytic residues, allosteric microdomains, transmembrane helices, signalling cofactors and cytoskeletal complexes. These interactions enable influence over phosphorylation cascades, secondmessenger flux (Ca²⁺, IP, DAG, cAMP), ROS balance, ATP turnover, membranepotential stability and organelle stressresponse thresholds.
Benefits and Applications
- Receptorligand affinity analysis and docking studies
- Enzymekinetic profiling and catalyticflux pathway mapping
- Mitochondrialfunction modelling and ATP/ROS system evaluation
- Transcriptomic, metabolomic, proteomic and phosphoproteomic profiling
- Cytoskeletalarchitecture and membranedynamics exploration
- Apoptosis, autophagy, necroptosis and ferroptosis pathway modelling
- SAR/QSAR modelling and compoundoptimisation workflows
- Mechanistic pharmacodynamics and doseresponse simulation
Side Effects and Risks
- Oxidativestress imbalance and elevated ROS
- Mitochondrial overload or respiratorychain suppression
- Disruption of Ca²⁺/Na⁺/K⁺ ionhomeostasis
- Unintended receptor crosstalk or inhibitory signal interference
- Cytoskeletal destabilisation and membrane-integrity reduction
- Dosedependent cytotoxicity or programmed-cell-death activation
- Transcriptional and epigenetic instability
- Inflammatorycascade activation (NF-κB, MAPK, JNK)
Only GMP materials will be supplied, logistics all according to GDP.
Datasheet
| Molecular Formula | C42H70O11 |
|---|---|
| Molecular Weight | 751.0 g/mol |
| CAS Number | 53003-10-4 |
| Storage Condition | Store in a cool, dry place. |
| Solubility | Solubility depends on solvent and conditions (e.g., pH). Please contact us for solvent-specific guidance. |
| Purity | Purity information is available upon request (COA). |
| Synonym | salinomycin; 53003-10-4; Procoxacin; Coxistac; Salinomicina |
| IUPAC/Chemical Name | (2R)-2-[(2R,5S,6R)-6-[(2S,3S,4S,6R)-6-[(3S,5S,7R,9S,10S,12R,15R)-3-[(2R,5R,6S)-5-ethyl-5-hydroxy-6-methyloxan-2-yl]-15-hydroxy-3,10,12-trimethyl-4,6,8-trioxadispiro[4.1.57.35]pentadec-13-en-9-yl]-3-hydroxy-4-methyl-5-oxooctan-2-yl]-5-methyloxan-2-yl]butanoic acid |
| InChl Key | KQXDHUJYNAXLNZ-XQSDOZFQSA-N |
| InChl Code | InChI=1S/C42H70O11/c1-11-29(38(46)47)31-15-14-23(4)36(50-31)27(8)34(44)26(7)35(45)30(12-2)37-24(5)22-25(6)41(51-37)19-16-32(43)42(53-41)21-20-39(10,52-42)33-17-18-40(48,13-3)28(9)49-33/h16,19,23-34,36-37,43-44,48H,11-15,17-18,20-22H2,1-10H3,(H,46,47)/t23-,24-,25+,26-,27-,28-,29+,30-,31+,32+,33+,34+,36+,37-,39-,40+,41-,42-/m0/s1 |
| References |
3D Conformer.
(Click, turn or enlarge)
Download our GMP API Product List.
MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.
